Dual antiplatelet therapy (DAPT) with Aspirin and P2Y12 receptor inhibitors remains the cornerstone therapy in Acute Coronary Syndrome (ACS) management. Among the P2Y12 inhibitors, Ticagrelor has shown higher potency and noteworthy clinical benefits in ACS. Further, the efficacy of Ticagrelor was also tested in many studies, the results from these studies revealed the reduced rate of myocardial infarction and stent thrombosis along with a reduction in overall mortality in ACS patients. 1,2 AstraZeneca and Docplexus have organized an interactive Webinar on 18th March 2020 at 1:30 PM . In this webinar session, Dr. Ashok Seth will discuss The Art Of Making The Right Choice On ACS Management .
We invite you to submit your questions which will be answered by the speaker at the end of the session. Reference: EFFECTIVENESS B. Brilinta™. Director. 2012;267:685-2682. Danielak D,…
